Clinical trials: Autologous Transplantation
Ovarian Cancer
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- ETC (NCT00005612)
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma in Relapse
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate…
- Trial name
- NCT03030261
- Testing
- Elotuzumab, Pomalidomide, Dexamethasone
- Where
- 3 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Kidney Transplant, Kidney Failure
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher.
- Conditions
- Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis
- Trial name
- NCT06056102
- Testing
- Cyclophosphamide, CART-BCMA, huCART19
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Non Hodgkin Lymphoma
Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation
The purpose of this study is to describe the kinetics of lymphocyte subsets reconstitution after growth factor administration, Pegfilgrastim versus Filgrastim in patients with B-cell malignant non-Hodgkin lymphoma treated with…
- Trial name
- PALM2 (NCT01541072)
- Testing
- Pegfilgrastim, Filgrastim
- Where
- 2 sites in France
- Volunteers
- 34 people
- Sponsor
- Centre Leon Berard
Multiple Myeloma
Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)
Intensification with autologous stem cell (ASCT) is currently the most effective treatment for subjects under 65 and the essential goal is to achieve complete response (CR) or very good partial response (VGPR= greater than 90%…
- Trial name
- NCT00642395
- Testing
- Bortezomib
- Where
- 34 sites in France
- Volunteers
- 61 people
- Sponsor
- University Hospital, Toulouse
Multiple Myeloma, Non-Hodgkin's Lymphoma
A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma
This research study is evaluating Enterade, a supplement, as a possible treatment for the side effects caused by Stem Cell Transplant.
- Trial name
- NCT02919670
- Testing
- Enterade, Standard Supportive Care
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Dana-Farber Cancer Institute
Wound Healing Disorder
Lipofilling for Healing of Chronic Wounds
Chronic wounds remain a therapeutic and financial challenge for physicians and the health care systems. Innovative, cheap and effective treatment methods would be of immense value.
- Trial name
- NCT05509673
- Testing
- Lipofilling (sublesional fat grafting)
- Volunteers
- 34 people
- Sponsor
- University of Witten/Herdecke
Diffuse Large Cell Lymphoma
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
This study is a multicentric trial evaluating the efficacy of R-ACVBP in patients aged 18 to 59 years with high risk diffuse large B-cell lymphoma
- Trial name
- NCT00144807
- Testing
- rituximab, doxorubicin, cyclophosphamide
- Where
- 13 sites in Belgium, France and 1 more
- Volunteers
- 128 people
- Sponsor
- Lymphoma Study Association
Malignant Lymphoma, Stem Cell Type, Autologous Transplant
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
The purpose of this study is to determine if the combination of G-CSF and bortezomib is safe and effective in blood cell mobilization.
- Trial name
- NCT01171092
- Testing
- bortezomib and G-CSF
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Kansas Medical Center
Oral Mucositis (Ulcerative)
Randomized Trial of Curcumin to Reduce Mucositis in Autologous Transplant Setting
Mucositis is a very common complication in bone marrow transplant setting. It is a result of injury to the gut caused by high dose chemotherapy.
- Trial name
- NCT04896164
- Testing
- Curcumin Lozenges
- Where
- India
- Volunteers
- 190 people
- Sponsor
- Tata Memorial Centre
Atopic Dermatitis, Eczema
Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival
Unlike healthy control skin, the skin of patients with atopic dermatitis (AD) is frequently colonized by Staphylococcus aureus (S. aureus), putting these patients at increased risk of S. aureus skin infections.
- Trial name
- NCT01960764
- Testing
- Pre-Treatment with Dial liquid antibacterial soap, Control
- Where
- United States
- Sponsor
- University of California, San Diego
Critical Limb Ischemia, Ischemia
HemaTrate™ in the Treatment of Critical Limb Ischemia
The primary objective of this study is to evaluate the performance of the HemaTrate™ Blood Filtration system in the treatment of critical limb ischemia.
- Trial name
- NCT03809494
- Testing
- HemaTrate™ Blood Filtration system, Saline
- Where
- 3 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- Cook Research Incorporated
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
This randomized phase III trial studies lenalidomide, dexamethasone, and bortezomib to see how well it works compared to dexamethasone and lenalidomide alone in treating patients with previously untreated multiple myeloma.
- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
- Trial name
- NCT00644228
- Testing
- Bortezomib, Dexamethasone, Laboratory Biomarker Analysis
- Where
- 498 sites in United States, Puerto Rico and 1 more
- Volunteers
- 525 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor
High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors
Study No.: KSPNO-S-081 Reduced-dose Craniospinal Radiotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Newly Diagnosed High-risk Brain Tumor Study No.: KSPNO-S-082 High-dose Chemotherapy…
- Trial name
- NCT00798811
- Testing
- high-dose chemotherapy and autologous stem cell rescue
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Multiple Myeloma
Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma
The study involves the use of a targeted form of radiation, in addition to standard high dose chemotherapy and stem cell transplant for multiple myeloma.
- Trial name
- NCT01207765
- Testing
- indium-111-ibritumomab tiuxetan, 90Y Zevalin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Tufts Medical Center
Lymphoma, Non-Hodgkin
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal…
- Trial name
- NCT00103610
- Testing
- Granulocyte colony-stimulating factor plus plerixafor
- Where
- 32 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Genzyme, a Sanofi Company
Pterygium, Ocular Surface Disease
Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
To evaluate the use of cultivated conjunctival epithelial equivalents for the treatment of ocular diseases
- Conditions
- Pterygium, Ocular Surface Disease, Stevens Johnson Syndrome, Chemical Injury
- Trial name
- NCT00346450
- Testing
- Cultivated conjunctival transplantation
- Where
- Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Singapore National Eye Centre
Lymphoma, Lymphoma, B-Cell
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT.
- Conditions
- Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Hodgkin
- Trial name
- NCT05540340
- Testing
- Pharmacokinetics
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Multiple myeloma (MM) is a common incurable blood cancer causing debilitating symptoms-bone pain, kidney failure, low blood counts and infection.
- Trial name
- NCT02331368
- Testing
- Autologous Stem Cell Transplant, Melphalan, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hematologic Diseases
A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants
This is a Phase 1,open label,safety,and efficacy study in subjects with non-β0/β0 TDT β-thalassemia Major by transplanting BD211 drug product which is for autologous use only,via a single IV administration.
- Trial name
- NCT05015920
- Testing
- BD211 Drug Product
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Shanghai BDgene Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.